SOCS2, suppressor of cytokine signaling 2, 8835

N. diseases: 104; N. variants: 8
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
0.010 AlteredExpression disease BEFREE SOCS2 was confirmed as a target of miR-875, and the expression of SOCS2 was markedly decreased in NSCLC tissues. 31298374 2019
CUI: C0022661
Disease: Kidney Failure, Chronic
Kidney Failure, Chronic
0.010 AlteredExpression disease BEFREE Lastly, we confirmed decreased AhR and increased SOCS2 expression in monocytes of patients with end-stage renal disease, indicating the activation of AhR. 31284759 2019
CUI: C0023465
Disease: Acute monocytic leukemia
Acute monocytic leukemia
0.010 Biomarker disease BEFREE SOCS2 is part of a highly prognostic 4-gene signature in AML and promotes disease aggressiveness. 31235852 2019
CUI: C0032285
Disease: Pneumonia
Pneumonia
0.010 Biomarker disease BEFREE These studies show KIAA0317 to be a critical mediator of pulmonary inflammation through its degradation of SOCS2 and a potential candidate target for therapeutic inhibition. 31578312 2019
CUI: C0376545
Disease: Hematologic Neoplasms
Hematologic Neoplasms
0.010 AlteredExpression group BEFREE Moreover, our analysis revealed that SOCS2 levels are significantly increased in patients with acute and chronic myeloid leukemia, two hematological malignancies where disease progression is closely linked to IL-1β. 31775389 2019
CUI: C0598766
Disease: Leukemogenesis
Leukemogenesis
0.010 Biomarker disease BEFREE SOCS2 promoted leukemogenesis as well as the abundance, quiescence, and activity of AML stem cells. 31235852 2019
CUI: C1739135
Disease: Progression of prostate cancer
Progression of prostate cancer
0.010 AlteredExpression disease BEFREE This study demonstrated that miR-492 was over-expressed in PCa and exerted tumor-promoting function in PCa cells via repressing SOCS2 expression. 30779065 2019
CUI: C2316810
Disease: Chronic kidney disease stage 5
Chronic kidney disease stage 5
0.010 AlteredExpression disease BEFREE Lastly, we confirmed decreased AhR and increased SOCS2 expression in monocytes of patients with end-stage renal disease, indicating the activation of AhR. 31284759 2019
CUI: C3714636
Disease: Pneumonitis
Pneumonitis
0.010 Biomarker disease BEFREE These studies show KIAA0317 to be a critical mediator of pulmonary inflammation through its degradation of SOCS2 and a potential candidate target for therapeutic inhibition. 31578312 2019
CUI: C0006852
Disease: Candidiasis of vagina
Candidiasis of vagina
0.010 Biomarker disease BEFREE Protective Effects of cis-2-Dodecenoic Acid in an Experimental Mouse Model of Vaginal Candidiasis. 30558702 2018
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon
0.010 AlteredExpression disease BEFREE Thus, SOCS2 was upregulated by p53 dysfunction and seemed to be associated with the tumorigenic potential of colon cancer. 29622769 2018
Leukoencephalitis, Acute Hemorrhagic
0.010 GeneticVariation disease BEFREE RqpR controls target gene expression by direct binding to DNA promoters, including the cis-2-dodecenoic acid (BDSF) and N-acylhomoserine lactone (AHL) signal synthase gene promoters. 29363827 2018
CUI: C0021390
Disease: Inflammatory Bowel Diseases
Inflammatory Bowel Diseases
0.010 AlteredExpression group BEFREE Therefore, it is likely that SOCS2 expression represents a critical mediator through which proinflammatory cytokines inhibit GH/IGF-1 signaling and decrease bone quality in IBD. 29343614 2018
CUI: C0029453
Disease: Osteopenia
Osteopenia
0.010 Biomarker disease BEFREE These studies indicate that the absence of SOCS2 is protective against bone loss typical of IBD. 29343614 2018
CUI: C0152013
Disease: Adenocarcinoma of lung (disorder)
Adenocarcinoma of lung (disorder)
0.010 Biomarker disease BEFREE Altogether, our results reveal an important role for SOCS2 dysregulation in the pathogenicity of lung adenocarcinoma, suggest its potential use as a biomarker for diagnosing lung adenocarcinoma, and paves the way to develop novel therapy targets as the axis of SOCS2-IGF1R-STAT in lung adenocarcinoma. 29559623 2018
CUI: C0220630
Disease: Adult Liver Carcinoma
Adult Liver Carcinoma
0.010 Biomarker disease BEFREE RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2. 29171881 2018
CUI: C0238463
Disease: Papillary thyroid carcinoma
Papillary thyroid carcinoma
0.010 Biomarker disease BEFREE Thus, SOCS-1, SOCS-2, and SOCS-3 proteins may directly or indirectly, have important roles in development and pathogenesis of papillary thyroid cancer. 28643757 2018
Liver and Intrahepatic Biliary Tract Carcinoma
0.010 Biomarker disease BEFREE RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2. 29171881 2018
CUI: C0280324
Disease: Laryngeal Squamous Cell Carcinoma
Laryngeal Squamous Cell Carcinoma
0.010 AlteredExpression disease BEFREE Overexpression of miR-196b suppresses SOCS2 in human LSCC resulting in tumor progression and poor prognosis. miR-196b is a potential marker for prognosis assessment and targeting miR-196b may be a novel valuable strategy for the treatment of LSCC. 29753737 2018
CUI: C0345904
Disease: Malignant neoplasm of liver
Malignant neoplasm of liver
0.010 Biomarker disease BEFREE RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2. 29171881 2018
CUI: C0699790
Disease: Colon Carcinoma
Colon Carcinoma
0.010 AlteredExpression disease BEFREE Thus, SOCS2 was upregulated by p53 dysfunction and seemed to be associated with the tumorigenic potential of colon cancer. 29622769 2018
CUI: C0700345
Disease: Candidiasis, Vulvovaginal
Candidiasis, Vulvovaginal
0.010 Biomarker disease BEFREE Protective Effects of cis-2-Dodecenoic Acid in an Experimental Mouse Model of Vaginal Candidiasis. 30558702 2018
CUI: C0015967
Disease: Fever
Fever
0.010 Biomarker phenotype BEFREE Complex cis-2 resulted from isomerization of trans-2 at elevated temperature. cis-[Re<sup>VI</sup>(O)<sub>2</sub>(pyxn)](PF<sub>6</sub>)<sub>2</sub> (1'·(PF<sub>6</sub>)<sub>2</sub>) was obtained by constant-potential electrolysis of 1·PF<sub>6</sub> in MeCN (0.1 M [NBu<sub>4</sub>]PF<sub>6</sub>) at 0.56 V vs SCE; it displays shorter Re-O distances (1.722(4), 1.726(4) Å) and a smaller O-Re-O angle (114.88(18)°) relative to 1 and shows a d-d transition absorption band at 591 nm (ε = 77 dm<sup>3</sup> mol<sup>-1</sup> cm<sup>-1</sup>).With a driving force of ca. 29190093 2017
CUI: C0017547
Disease: Gigantism
Gigantism
0.010 Biomarker disease BEFREE SOCS2 is a pleiotropic E3 ligase.Its deficiency is associated with gigantism and organismal lethality upon inflammatory challenge. 28216640 2017
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.010 Biomarker disease BEFREE Hepatitis B Virus e Antigen Activates the Suppressor of Cytokine Signaling 2 to Repress Interferon Action. 28496097 2017